Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REIC gene therapy - Momotaro-Gene

Drug Profile

REIC gene therapy - Momotaro-Gene

Alternative Names: Ad5-SGE-REIC/Dkk-3; DKK3 gene therapy - Momotaro-Gene; MTG-201; REIC/Dkk-3 gene therapy

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Momotaro-Gene
  • Developer Icahn School of Medicine at Mount Sinai; Kyorin Pharmaceutical; Momotaro-Gene
  • Class Antineoplastics; Cancer vaccines; Gene therapies
  • Mechanism of Action Apoptosis stimulants; DKK3 expression modulators; Gene transference; Tumour suppressor gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Mesothelioma
  • Phase I/II Prostate cancer
  • No development reported Liver cancer

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for preclinical development in Liver-cancer in USA (Intratumoural, Injection)
  • 11 Sep 2019 Pharmacodynamics data from a preclinical study in Mesothelioma released by Momotaro-Gene
  • 11 Sep 2019 Kyorin Pharmaceuticals completes a phase I/II trial in Mesothelioma in Japan (JapicCTI-152998)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top